Coherus BioSciences Inc (CHRS)

Coherus BioSciences Inc (CHRS) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $156M; returns 1 day -3.8%, 1 week +2.0%, 1 year -39.5%.

Coherus BioSciences, Inc. (CHRS), is a commercial-stage biopharmaceutical company focused on immuno-oncology. The company develops and commercializes both biosimilar and innovative therapies. Coherus generates revenue primarily through product sales, licensing agreements, and strategic collaborations.

Groups CHRS belongs to

• Biotechnology
• Biopharmaceutical
• Commercial Stage
• Oncology
• Healthcare
• Commercial Stage Biotech
• Immunotherapy
• Cancer Therapeutics
• PD-L1
• Antibody Therapeutics
• Biologics
• Monoclonal Antibodies

CHRS financial model: income statement, cash flow and balance sheet